Limited proteolysis of tumor cells increases their plasmin-binding ability.
Mild proteolytic treatment of SW1116 tumor cells with trypsin or plasmin increases their plasmin-binding ability considerably by increasing the number of binding sites without altering their affinity. This mechanism may be operative for increasing the concentration of active plasmin at the surface of tumor cells. C-terminal lysine residues are involved in plasmin binding to cells, since treatment of cells with carboxypeptidase B decreases this binding by 50%.
Camacho
M
M
UPR 5; IRSC, Villejuif, France.
Fondaneche
M C
MC
Burtin
P
P
D007611:Aprotinin / Q000494:pharmacology; D043424:Carboxypeptidase B; D002268:Carboxypeptidases / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D005340:Fibrinogen / Q000502:physiology; D005341:Fibrinolysin / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D010447:Peptide Hydrolases / Q000494:pharmacology*; D014357:Trypsin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D005340:Fibrinogen; D007611:Aprotinin; D002268:Carboxypeptidases; D010447:Peptide Hydrolases; D043424:Carboxypeptidase B; D014357:Trypsin; D005341:Fibrinolysin